A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Non-Small Cell Lung Cancer|Medullary Thyroid Cancer|Colon Cancer|Any Solid Tumor
Interventions: DRUG: LOXO-292
Sponsor: Loxo Oncology, Inc.
Collaborators: Eli Lilly and Company